tion is obscure. Probably part of the decrease of heart rate can be explained by the lengthening of PQ-duration.
P-223 THE COMBINATION OF OLMESARTAN MEDOXOMIL PLUS HYDROCHLOROTHIAZIDE IN SUBJECTS WITH STAGE 2 HYPERTENSION: RESULTS OF A RANDOMIZED, DOUBLE-BLIND, FACTORIAL-DESIGN STUDY
According to JNC 7 guidelines, patients classified as having stage 2 hypertension will likely require 2 or more agents to achieve blood pressure (BP) goals of Ͻ140/90 mm Hg (Ͻ130/80 mm Hg for patients with diabetes or chronic renal disease). A randomized, double-blind, factorial-design study in hypertensive patients demonstrated that the combination of olmesartan medoxomil/hydrochlorothiazide (OLM/ HCTZ) provided substantial reductions in systolic blood pressure/diastolic blood pressure (SBP/DBP) that were significantly greater than monotherapy with either agent alone. To put these BP reductions into perspective, we assessed the BP control rates for this same population of patients. Five hundred two patients with a baseline mean seated DBP (SeDBP) of 100 to 115 mm Hg were randomized to placebo; OLM 10, 20, or 40 mg/day; HCTZ 12.5 or 25 mg/day; or OLM/HCTZ combination therapy. The primary efficacy variable was change from baseline in mean trough SeDBP at week 8. Secondary efficacy variables included the change from baseline in mean trough SeSBP; responder rates (SeDBP Ͻ90 mm Hg or Ն10 mm Hg reduction); and control rates (SeSBP Ͻ140 or Ͻ130; SeDBP Ͻ90 or Ͻ85 mm Hg Background: There is a lot of debate about the selection of the most appropriate treatments for hypertension. Most treatment recommendations are based on criteria that consider efficacy, safety and cost. Given the need for long-term utilization of these agents, treatment compliance should also be taken into consideration in the selection process.
Objective: The purpose of this study was to estimate persistence and adherence to antihypertensive agents in a real life setting.
Methods: This study was performed using data from the Regie de l'assurance maladie du Quebec (RAMQ). Persistence and adherence to treatment were estimated separately and an index combining these two measures was calculated. Persistence to treatment was calculated as the proportion of patients who had not definitively abandoned their treatment two years after they started it. Adherence to treatment was calculated as the proportion of patients for whom the ratio of the quantity of medication received over the quantity needed for the treatment period was above 80%. The persistence-adherence index was calculated by multiplying the monthly persistence rates by the monthly adherence rates over a two-year period.
Results: Data from a random sample of 64,175 subjects covered by the RAMQ drug plan and one of the antihypertensive agent reimbursed by the drug plan for the first time between January 1999 and December 2000 were analysed. After a two-year period, persistence to treatment varied across antihypertensive agents. Persistence rates to ␤-blockers, amlodipine, angiotensin II receptor antagonists, other calcium channel blockers, ACE inhibitors, other diuretics, hydrochlorothiazide, and chlorthalidone The acute effects of Nebivolol (NEB), a beta-blocker which activates the NO-pathway, and Metoprolol (MET) on nitric oxide (NOx) urinary excretion, blood pressure (BP) and on protein expression of endothelial nitric oxide synthase (eNOS) in thoracic/abdominal aortae were studied in spontaneously hypertensive rats (SHR). NOx excretion was studied by sampling urine every 12 h after i.p. inj. of NEB (30mg/kg) or MET (30mg/kg) at 7 and 19h. BP was measured by telemetry after i.p. inj. of NEB (3,10,30 mg/kg) or MET (1.98, 6.59, 30, 100 mg/kg) at 7 and 19h. Thoracic and abdominal aortae were withdrawn 24 hours after NEB (30 mg/kg) injection at 7h to determine eNOS protein expression by Western blot. NEB significantly increased NOx excretion, most marked 12-24h after drug dosing, whereas MET had no effect. Effects of MET and NEB on BP were only dose-dependent when given at 19h: Max. was reached by MET after 30 min (Ϫ21mmHg) and by NEB after 3 hours (Ϫ30mmHg). NEB lowered BP for several days, MET only for some hours. eNOS protein expression was not affected by NEB: control vs NEB in thoracic (OD: 85.8 Ϯ 18.3 and 94.2 Ϯ 19.8, resp) in abdominal aortae (OD: 113.2 Ϯ. 11.3 and 125.3 Ϯ 11.7, resp). Thus, NEB in contrast to MET affected the NO-pathway by enhancing NOx production, eNOS protein expression was not influenced. Increased NOx excretion by NEB was completely prevented by the NO-synthase inhibitor L-NAME. The increased NOx excretion must be due to increased activity of eNOS. The two betablockers also vary in onset and duration of decreasing BP. The longlasting effect of NEB may be due to active metabolites.
Support: Berlin-Chemie, Berlin, Germany Key Words: Nebivolol and Metoprolol, Nitric Oxide, SpontaneouslyHypertensive Rats Pavel J Levy, Ronald D Smith, Bridget Brosnihan, John Owen, Mark Espeland, Carlos M Ferrario. Hypertension and Vascular Disease Center, Wake Forest University School of Medicine, Winston-Salem, NC; Hematology and Oncology, Wake Forest University School of Medicine, Winston-Salem, NC; Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC. Clinically evident atherosclerotic cardiovascular disease (ASCVD) is a pro-inflammatory state associated with increased platelet aggregability (PAGG) and activation of the renin angiotensin system. Objectives: We hypothesize that: a) in hypertensive patients a selective angiotensin II AT 1 receptor antagonist Irbesartan (IRB) in addition to its hypotensive effect may also contribute to reduction of PAGG and of plasma markers of inflammation; b) these effects of IRB are different in patients with and without ASCVD. 
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